The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

Viking Therapeutics, Inc. (NASDAQ: VKTX) director J. Matthew Singleton executed a sale of company stock valued at more than $715,000, according to a recent SEC filing. The transactions, which took ...

Both Adzenys and Adderall are stimulant-based drugs that target neurotransmitters in the brain, but there are some ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...

Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in PatientsMUNICH, Sept. 18, 2024 (GLOBE NEWSWIRE) -- ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...